Evidence map›Paper›PMID 28259941›Full record

Trial reportInternational journal of molecular medicine2017

Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects.

Jae-Yong Kim, Seong-Min Kim, Suk-Jeong Kim, Eun-Young Lee, Jae-Ryong Kim, Kyung-Hyun Cho

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in International journal of molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Multiple functions of policosanol in elderly patients with dyslipidemia.The Journal of international medical research · 2020
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Combination of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Synergistic Effect of Banaba Leaf Extract and Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Synergistic Efficacy of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2025
    Article
  16. Article
  17. Comparison of the In Vivo Efficacy of Cuban (RaydelPharmaceuticals (Basel, Switzerland) · 2024
    Article
  18. Article
  19. Potential Therapeutic Effects of Policosanol from Insect Wax on Caenorhabditis elegans Models of Parkinson's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jae-Yong KimDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
Seong-Min KimDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
Suk-Jeong KimDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
Eun-Young LeeDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
Jae-Ryong KimDepartment of Biochemistry and Molecular Biology, College of Medicine, Yeungnam University, Daegu 705-717, Republic of Korea.
Kyung-Hyun ChoDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
Yeungnam University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well-known that policosanol can improve serum lipid profiles, although the physiological mechanism is still unknown. Here, we investigated functional and structural changes in lipoproteins after consumption of policosanol. To investigate the physiological effect of policosanol, we analyzed serum parameters in young non-smoker (YN; n=7, 24.0±2.4 years), young smoker (YS; n=7, 26.3±1.5 years), and middle-aged subjects (MN; n=11, 52.5±9.8 years) who consumed policosanol daily (10 mg/day) for 8 weeks. After 8 weeks, systolic blood pressure was significantly lowered to 4% (7 mmHg, p=0.022) from initial levels in the YS and MN groups. Moisture content of facial skin increased up to 38 and 18% from initial levels in the YS and MN groups, respectively. Serum triglyceride (TG) levels decreased to 28 and 26% from initial levels in the YN and MN groups, respectively. The percentage of high-density lipoprotein-cholesterol (HDL-C) in total cholesterol was elevated in all subjects (YN, 36%; YS, 35%; MN, 8%) after 8 weeks of policosanol consumption. All groups showed a reduction in serum glucose and uric acid levels. Serum cholesteryl ester transfer protein (CETP) activity was significantly diminished up to 21 and 32% from initial levels in the YN and MN groups, respectively. After 8 weeks, oxidation of the low-density lipoprotein fraction was markedly reduced accompanied by decreased apolipoprotein B (apoB) fragmentation. In the HDL fraction, paraoxonase activity was elevated by 17% along with elevation of apoA-I and cholesterol contents. Electron microscopy revealed that the size and number of HDL particles increased after 8 weeks, and the YS group showed a 2-fold increase in particle size. Daily consumption of policosanol for 8 weeks resulted in lowered blood pressure, reduced serum TG level and CETP activity, and elevated HDL-C contents. These functional enhancements of HDL can prevent and/or attenuate aging-related diseases, hypertension, diabetes and coronary heart disease.

Indexed as

AdultBlood PressureCholesterol Ester Transfer ProteinsCholesterol, HDLCoronary DiseaseDiabetes MellitusFatty AlcoholsHumansHypertensionIntra-Abdominal FatMaleMiddle AgedTime FactorsTriglyceridesCETP protein, humanCholesterol Ester Transfer ProteinsCholesterol, HDLFatty AlcoholspolicosanolTriglycerides

Identifiers

PMID28259941
PMCPMC5360427
OpenAlexW2590627201

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.